Summary: A trial involving 90 adults with overweight or obesity tested a specific pasteurised Akkermansia muciniphila preparation after an eight-week low-energy diet. Weight regain during 24-week maintenance was 1.2 kg with the preparation versus 3.2 kg with placebo (P=0.012). This was a weight-maintenance study, not proof of lasting obesity treatment benefit.
PICO Summary
| Element | Detail |
|---|---|
| Population | 90 adults with overweight or obesity entered a programme involving an eight-week low-energy diet targeting at least 8% weight loss, followed by a 24-week maintenance phase. Applicability is to this selected dietary-treatment setting. |
| Intervention | Daily supplementation with the study-specific pasteurised Akkermansia muciniphila MucT preparation during the 24-week maintenance phase, alongside a healthy ad libitum diet. The source abstract does not provide a dose for clinical implementation. |
| Comparator | Placebo supplementation during the same maintenance phase and dietary programme. The study does not establish interchangeability with other commercial preparations or live bacterial products. |
| Outcomes | Primary endpoint: body-weight change during maintenance. Reported mean regain was 1.2 kg with MucT versus 3.2 kg with placebo (P=0.012), equivalent to 2.0 kg less regain by subtraction of the group means. The abstract does not provide a confidence interval for that contrast. No treatment-related serious adverse events were reported. Baseline Akkermansia abundance was associated with response, but that does not validate a clinical selection test. Longer-term clinical outcomes were not established. |
| Study Design | Randomised placebo-controlled weight-maintenance trial; eight-week initial dietary phase followed by 24-week supplementation. NCT05417360. Company leadership, employees, a scientific adviser and related patent inventors were among the authors. Evidence here is limited to the specific tested preparation and regimen. |
Expert Commentary
I consider this an interesting maintenance signal, but not a reason to recommend microbiome supplements as a class. The trial asked whether a particular pasteurised preparation reduced regain after successful dietary weight loss. That is a narrower question than whether taking an over-the-counter product causes weight loss in an unselected population. Can I use this with my patients? The study can support an evidence-based conversation about emerging approaches, while making clear that it does not establish a standard supplement recommendation. The most important limitation is the short maintenance period in a selected dietary programme. A two-kilogram difference in regain may matter, but its persistence and effect on health outcomes remain uncertain. The reported association with baseline bacterial abundance should not be repackaged as a validated microbiome test for choosing treatment. Likewise, the absence of treatment-related serious adverse events in a small study does not establish long-term safety. The authors' company and patent relationships deserve transparent discussion, particularly when translating findings into consumer claims. I would want replication of the exact formulation, fuller comparative safety data and longer follow-up before positioning this approach alongside established obesity care. Future reports should show which patients benefit, how durable the effect is and whether any benefit exceeds the demands of continued supplementation.
References
Mount S, Canfora EE, Jocken JW, et al. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nat Med. 2026;32(6):2107-2116. doi:10.1038/s41591-026-04394-7. PMID: 42120725.
